Close Menu

Strata Oncology

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.

Within the partnership, Strata Oncology will use its StrataNGS test to identify patients with NRG1 gene fusions who may be eligible to enroll in a Phase II trial for the drug.

The companies are using Strata's biomarker technology to identify genomic subpopulations of cancer patients who respond to Arcus' investigational immunotherapy drug.

The study is testing the efficacy of cancer treatments that are selected based on genomic markers driving patients' tumors, regardless of cancer type.